Skip to content

Sacrospinous Ligament Fixation With Conventional Surgical Instruments in Chinese Apical Prolapse Female Patients

Sacrospinous Ligament Fixation With Conventional Surgical Instruments in Chinese Apical Prolapse Female Patients: a Multi-center Prospective Clinical Trial

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03782285
Acronym
SSLF-CSI
Enrollment
100
Registered
2018-12-20
Start date
2018-11-23
Completion date
2019-09-30
Last updated
2018-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse

Keywords

apical prolapse, sacrospinous Ligament Fixation

Brief summary

SSLF is typically a suture-based attachment of the vaginal apex to the sacrospinous ligament, either unilaterally or bilaterally. It is usually accomplished with specially designed equipment in English-language scientific literature. However, these instruments either reusable or disposable are relatively expensive and difficult in accessibility, and are not yet widely applied around China. Typical Asian smaller pelvis offers us an optional repair procedure with conventional surgical instruments instead of special instrument.

Detailed description

Apical prolapse is defined as descent of the uterus and cervix, the cervix alone, or the post-hysterectomy vaginal cuff down to the hymen, lower vagina, or past the introitus. Among 684,250 POP procedures that were performed in 15 Organization for Economic Co-operation and Development (OECD) countries in 2012, apical compartment repairs represented 20% of these procedures. Sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. SSLF is typically a suture-based attachment of the vaginal apex to the sacrospinous ligament, either unilaterally or bilaterally usually with specially designed equipment such as Deschamps ligature carrier or Miya hook. However, these instruments are expensive and are not yet widely applied in China. Typical Asian smaller pelvis offers us an optional repair procedure with conventional surgical instruments instead of special instrument. Previous pilot study from Peking Union Medical College Hospital showed promising curative results with conventional surgical instruments in Chinese female patients. The investigation may show us a feasible, economic and effective modified procedure for Asian patients with medium compartment prolapse. This is a multi-center, prospective clinical trial. Previous studies using conventional surgical instruments for 1-year follow-up showed objective cure rate was 98%, subjective satisfaction was 94%, Considering that the objective cure rate may decrease in multicenter trials, it is assumed that the objective cure rate of multicenter trials can reach 95%. When the sample size is at least 79 patients, 80% of the test efficiency can verify that the objective cure rate is higher than the target value when the bilateral α=0.05. The missing rate was about 10%. The incidence of SSLF failure requiring other operations method due to deep pelvic cavity and unsatisfactory exposure by conventional instruments was about 5%. The final number of cases included in this study should be 100 cases. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia. The research units will collect perioperative data and complete unified format case report form (CRF) for all selected patients for further analysis. A total of at most 9 months will be required to complete the study after starting up.

Interventions

sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.

Sponsors

First Hospitals affiliated to the China PLA General Hospital
CollaboratorOTHER_GOV
Shanghai First Maternity and Infant Hospital
CollaboratorOTHER
The Second Hospital of Anhui Medical University
CollaboratorOTHER
Shanxi Provincial Maternity and Children's Hospital
CollaboratorOTHER
Foshan Women's and Children's Hospital
CollaboratorOTHER
Suzhou Municipal Hospital
CollaboratorOTHER
Chongqing Maternal and Child Health Hospital
CollaboratorOTHER
Hangzhou Maternal and Child Health Hospital
CollaboratorUNKNOWN
Beijing Obstetrics and Gynecology Hospital
CollaboratorOTHER
Peking Union Medical College
CollaboratorOTHER
St. Francis Hospital, Chicago, USA
CollaboratorUNKNOWN
University of Texas, Southwestern Medical Center at Dallas
CollaboratorOTHER
Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

1. Women with apical prolapse with POP-Q III or IV 2. Unilateral (all sutured to right sacrospinous ligament) SSLF is planned,while with vaginal hysterectomy, anterior/posterior vaginal wall repair or mid-urethral suspension could be performed simultaneously. 3. Women who have been eligible for long-term follow-up. 4. Women who agreed to participate in the study and signed informed consent.

Exclusion criteria

1. Women who have surgical history for prolapse 2. Women who have contraindication for surgical procedure 3. Women who are unable to comply with the study procedures

Design outcomes

Primary

MeasureTime frameDescription
Success rate of SSLF with conventional instrumentsup to 36 months after operation1. Symptomatic prolapse below grade II occurred at 3 months after operation, and the severest indication point in POP-Q evaluation was taken as the criterion. No vaginal swelling sensation, that is answer no for PFDI-20 Questionnaire Question 3, Do you often see or feel vaginal tumors come out?. 2. The patient's self-perception symptoms is improved or improved significantly, that is answer 1 or 2 for the PGI-C questionnaire. 3. There is no need of further treatment for prolapse, such as reoperation or pessary. 4. Pelvic MRI evaluation on postoperative 3 months follow-up

Secondary

MeasureTime frameDescription
visual analogue scaleswithin 3 days after operationpostoperative pain evaluation esp. hip pain by visual analogue scales (VAS). Visual Analogue Scale (VAS) is a self-report measure consisting simply of a 10 centimeter line with a statement at each end representing one extreme of the dimension being measured (most often intensity of pain)
symptomatic improvement using validated instruments(PFIQ-7)up to 36 months after operationRelief of symptoms using validated instruments, pelvic floor impact questionnaire short form 7(PFIQ-7)。PFIQ-7 scores 0-300, the higher the severer negative influence on patient.
Postoperative recurrencefrom 3 months after operation up to 36 months after operationEvaluation on the prolapse of the anterior, middle and posterior pelvic confirms POP-Q II degrees and above.
symptomatic improvement using validated instruments(PISQ-12)up to 36 months after operationRelief of symptoms using validated instruments, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form(PISQ-12), PISQ-12 scores 0-48, the higher, the severer negative influence on patient.
symptomatic improvement using patient global impression of change (PGI-C)up to 36 months after operationRelief of symptoms using patient global impression of change (PGI-C), PGI-C scores 1-7, the higher, the the severer negative influence on patient.
symptomatic improvement using validated instruments(PFDI-20)up to 36 months after operationRelief of symptoms using validated instruments, pelvic floor distress inventory short form 20(PFDI-20), PFDI-20 scores 0-300, the higher the severer negative influence on patient.

Countries

China

Contacts

Primary ContactYuxin Dai, MD
helen81918@163.com0086-010-69156204
Backup ContactLan Zhu, MD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026